190 related articles for article (PubMed ID: 28655808)
21. Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.
Baccarani M; Gale RP
Leukemia; 2021 Aug; 35(8):2199-2204. PubMed ID: 34002028
[No Abstract] [Full Text] [Related]
22. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Radich JP; Mauro MJ
Hematol Oncol Clin North Am; 2017 Aug; 31(4):577-587. PubMed ID: 28673389
[TBL] [Abstract][Full Text] [Related]
24. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
25. Marked discordance between cytogenetic/molecular and morphologic findings in a patient with chronic myeloid leukemia.
Rashidi A; Courville E
Blood Cells Mol Dis; 2017 Mar; 63():32-33. PubMed ID: 28110131
[No Abstract] [Full Text] [Related]
26. Present results and future perspectives in optimizing chronic myeloid leukemia therapy.
Carella AM; Saglio G; Mahon XF; Mauro MJ
Haematologica; 2018 Jun; 103(6):928-930. PubMed ID: 29866888
[No Abstract] [Full Text] [Related]
27. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
Kantarjian H; Cortes J
J Clin Oncol; 2011 Apr; 29(12):1512-6. PubMed ID: 21422414
[No Abstract] [Full Text] [Related]
28. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
[No Abstract] [Full Text] [Related]
29. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
Maiti A; Cortes J; Ferrajoli A; Estrov Z; Borthakur G; Garcia-Manero G; Jabbour E; Ravandi F; O'Brien S; Kantarjian H
Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28278723
[No Abstract] [Full Text] [Related]
30. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Hehlmann R; Lauseker M; Jung-Munkwitz S; Leitner A; Müller MC; Pletsch N; Proetel U; Haferlach C; Schlegelberger B; Balleisen L; Hänel M; Pfirrmann M; Krause SW; Nerl C; Pralle H; Gratwohl A; Hossfeld DK; Hasford J; Hochhaus A; Saussele S
J Clin Oncol; 2011 Apr; 29(12):1634-42. PubMed ID: 21422420
[TBL] [Abstract][Full Text] [Related]
31. Pediatric chronic myeloid leukemia with myeloid blast crisis and complex karyotype at presentation.
Sazawal S; Singh K; Chhikara S; Chaubey R; Mishra P; Seth T; Saxena R
Indian J Cancer; 2020; 57(3):343-345. PubMed ID: 32769290
[No Abstract] [Full Text] [Related]
32. Mutant BCR-ABL clones in chronic myeloid leukemia.
Mathisen MS; Kantarjian HM; Cortes J; Jabbour E
Haematologica; 2011 Mar; 96(3):347-9. PubMed ID: 21357713
[No Abstract] [Full Text] [Related]
33. Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
Hackanson B; Rückert A; Lübbert M
Eur J Haematol; 2009 Dec; 83(6):611-2. PubMed ID: 19682063
[No Abstract] [Full Text] [Related]
34. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
35. Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?
Mukhopadhyay A; Helgason GV; Karvela M; Holyoake TL
Expert Rev Hematol; 2011 Aug; 4(4):369-71. PubMed ID: 21801126
[No Abstract] [Full Text] [Related]
36. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
[TBL] [Abstract][Full Text] [Related]
37. Chronic myeloid leukemia: Second-line drugs of choice.
Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R
Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
[No Abstract] [Full Text] [Related]
39. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
40. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
